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Abstract
Introduction: The ketogenic diet (KD) is a high-fat, low-carbohydrate diet that alters metabolism by increasing the level of
ketone bodies in the blood. KetoCalH (KC) is a nutritionally complete, commercially available 4:1 (fat: carbohydrate+protein)
ketogenic formula that is an effective non-pharmacologic treatment for the management of refractory pediatric epilepsy.
Diet-induced ketosis causes changes to brain homeostasis that have potential for the treatment of other neurological
diseases such as malignant gliomas.
Methods: We used an intracranial bioluminescent mouse model of malignant glioma. Following implantation animals were
maintained on standard diet (SD) or KC. The mice received 264 Gy of whole brain radiation and tumor growth was followed
by in vivo imaging.
Results: Animals fed KC had elevated levels of b-hydroxybutyrate (p=0.0173) and an increased median survival of
approximately 5 days relative to animals maintained on SD. KC plus radiation treatment were more than additive, and in 9 of
11 irradiated animals maintained on KC the bioluminescent signal from the tumor cells diminished below the level of
detection (p,0.0001). Animals were switched to SD 101 days after implantation and no signs of tumor recurrence were
seen for over 200 days.
Conclusions: KC significantly enhances the anti-tumor effect of radiation. This suggests that cellular metabolic alterations
induced through KC may be useful as an adjuvant to the current standard of care for the treatment of human malignant
gliomas.
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Introduction
Malignant brain tumors are a devastating disease with a high
mortality rate. These tumors do not have defined boundaries and
complete surgical removal is virtually impossible. In addition, the
intrinsic heterogeneity and genetic instability in these tumors
results in cells resistant to therapy. Thus, even after surgery,
radiation and chemotherapy these tumors typically recur, leading
to patient mortality and an average survival of approximately 1.5
years [1]. Increased survival of brain tumor patients requires the
design of new therapeutic modalities, especially those that enhance
currently available therapies and/or limit tumor growth. Advances
in our understanding of the biology of these tumors has led to an
increase in the number of targeted therapies in preclinical and
clinical [2–4]. While these therapies may prove somewhat
effective, the heterogeneity of this tumor often precludes the
targeted molecules from being found on all cells in the tumor thus
reducing the efficacy of these treatments. In contrast, one trait
shared by virtually all tumor cells is altered metabolism.
Metabolic dysregulation of cancer cells was first described in the
1950s by Otto Warburg, who identified differences in glucose
uptake and production of lactate between non-neoplastic and
neoplastic cells, now referred to as the ‘‘Warburg Effect’’ [5]. The
‘‘Warburg Effect’’ refers to the tumor’s use of aerobic glycolysis to
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36197provide energy as well as biomolecules for growth regardless of the
availability of oxygen. Dysregulation of genes involved in glycolysis
and glycolytic transport to the mitochondria of tumor cells has
been reported, as have alterations to the mitochondria themselves
[6]. Metabolic dysregulation can also be a result of loss of p53 and
subsequent upregulation of serine-threonine protein kinase (Akt)
which can lead to the production of an overabundance of ATP [7].
Because all cancers share metabolic dysregulation and unregulated
production of energy due to these or other mechanisms, a therapy
that exploits this trait is likely to have a broader impact than an
individual targeted therapy. The ketogenic diet alters cellular
metabolism and thus may have a broad impact on overall tumor
growth [8–12].
We and others have demonstrated that the use of a ketogenic
diet and/or caloric restriction causes a reduction in blood glucose,
an elevation in blood ketones and extends life in mouse models of
malignant brain tumors. In our previous work [13] we demon-
strated that an approximate 6:1 (fat: protein+carbohydrates)
rodent ketogenic diet (KD; Bioserv F3666 diet, Bioserv, French-
town, NJ) not only increases survival, it also reduces reactive
oxygen species (ROS) and alters the expression of genes involved
in oxidative stress. This work also showed that overall gene
expression in the tumor from animals fed a ketogenic diet was
shifted more towards the gene expression seen in non-tumor-
containing tissue from animals fed either the ketogenic diet or
standard diet. Seyfried and co-workers have used a ketogenic diet
and/or caloric restriction to demonstrate that elevating ketones
prolongs survival in additional mouse models of glioma [14–16].
Since radiation following surgery has been shown to be the most
effective adjuvant therapy for patients with high-grade gliomas, we
analyzed the effect of a ketogenic diet on the anti-tumor activity of
radiation. For these studies we used KetocalH (SHS International
Ltd, Liverpool L7 9PT, UK), a nutritionally complete powdered
product used to administer the classical (4:1) ketogenic diet for
children over 1 year of age. We found that KetocalH (KC) fed ad
libitum significantly increased survival in both untreated animals
and in animals treated with radiation above that seen with animals
fed a standard diet alone or in combination with radiation.
There have been many investigations on the use of formulations
of the ketogenic diet for the treatment of various neurodegener-
ative diseases due, at least in part, to its neuroprotective properties
[17]. In addition, alternative metabolic treatments including long
and short-term fasting and/or calorie restriction have been
studied. [18]. Although others have investigated the use of varying
formulations of the ketogenic diet in glioma [19], to the best of our
knowledge, this study is the first to investigate the efficacy of this
formulation of the ketogenic diet in combination with radiother-
apy for the treatment of malignant glioma.
Results
KetoCalH Alone Prolonged Survival Following Tumor
Implantation
Kaplan-Meier analyses of the survival data (Figure 1A) dem-
onstrated a statistically significant (p,0.005) difference in median
survival between animals fed SD (23 days) versus those fed KC (28
days). This increased survival was comparable to our previously
reported results obtained on a smaller cohort of animals fed a
,6:1 (fat:carbohydrate+protein) rodent ketogenic diet (Bio-Serv
F3666 diet) [13]; however, in that experiment the maximum
survival of animals fed the rodent ketogenic diet was only 5 days
longer than the maximum survival of animals on the standard diet.
In this report, maximum survival of animals fed SD was 33 days
compared to 43 days in the group maintained on KC. One animal
on KC alone was apparently cured of its tumor as evidenced by
the loss of bioluminescent signal. On day 101 the animal was put
back on standard rodent chow with no evidence of tumor re-
growth for an additional 200 days, at which time the animal was
sacrificed and had no histological evidence of disease.
KetoCalH plus Radiation Treated Animals Were
Apparently Cured of Implanted Tumor
It is unlikely that any new treatment will be tried in patients
without some form of additional standard therapy. We therefore
tested KC in addition to radiation to determine if the effect of the
two treatments would be more than additive. Nine out of the 11
animals treated with KC in combination with radiation were
Figure 1. KetoCalH enhances survival of glioma-bearing mice. Kaplan-Meier plot of survival in KC versus SD (A), radiation versus KC plus
radiation (B). Animals on KC survived significantly longer when treated with KC alone (p,0.005), or when combined with radiation (p,0.0001).
Results are a combination of (A) 4 separate experiments and (B) 2 separate experiments.
doi:10.1371/journal.pone.0036197.g001
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imaging data from one representative animal treated with
radiation alone and one treated with radiation and KC is shown
in Figure 2. After an initial period of slower growth (Figure 2B,
inset), there was rapid tumor growth in the animals fed SD and
treated with radiation until the animal succumbed to the tumor
(Figure 2A, B) with a final photon count of 6.995610
9 p/sec/
cm
2/sr on day 39 following tumor implantation. In the animal
treated with radiation and KC the presence of growing tumor can
be seen for the first 1.5–2 weeks following implantation, reaching a
maximum bioluminescent signal of 1.258610
7 p/sec/cm
2/sr on
day 9 following tumor implantation. This was followed by a near
exponential decline that approaches background levels 60 days
following implantation. Bioluminescence remained undetectable
and on day 104 post-implantation the 9 surviving animals treated
with radiation and KC were switched from KC to the standard
rodent chow. There was no detectable recurrence of tumor as
demonstrated by the continued absence of detectable biolumines-
cent signal. The animals were sacrificed on day 299. Histological
evidence upon necropsy using hematoxylin and eosin (H&E)
staining of brain tissue from the apparently cured KC plus
radiation animals showed no evidence of tumor cells in or near the
area of implantation (data not shown).
Survival data from SD alone, KC alone, SD+radiation, and
KC+radiation were examined for interaction effects using Cox
Proportional Hazards. The p-value for radiation and KC is
p=1.03610
211 vs. SD. The implication being that there is a
profound enhancing (by mean survival) effect of radiation with KC
vs. SD alone. There is also an enhancing effect of radiation with
SD (p=8.38610
22) but the effect is many orders of magnitude
less. Thus, we propose that a more than additive and highly
positive survival effect is seen through the KC diet and adjuvant
radiation therapy.
Animals Fed KetoCalH Exhibit Elevated bHB levels
Animals fed KC had a statistically significant increase in blood
bHB levels (Figure 3A) both 6 and 13 days post-implantation. The
greatest increase in bHB levels was seen in animals given adjuvant
radiation therapy. However, increased bHB levels did not
correlate with a decrease in blood glucose levels. Glucose levels
were significantly lower in the KC and KC plus radiation groups
on day 6 (p,0.0001) than SD and SD plus radiation; and only in
the KC group on day 13 (p,0.001) when compared to SD.
KC diet itself had very little effect on the animal’s body weight,
indicating that the diet itself was tolerable. Body weight remained
very close to the starting weight in animals that were changed to
KC three days following implantation. Eighteen days following
implantation, body weights for SD and KC fed animals start to
decline slowly as symptoms began to present (Figure 4A). Weight
loss just prior to death is a function of the onset of symptoms due
to tumor burden and not KC treatment.
Animals fed KC and treated with radiation saw a noticeable dip
in weights 3–6 days following treatment (Figure 4B), indicating
that combination therapy had an effect on body weight. These
animals rapidly gained their weight back and there was no
difference between the 2 groups by day 15. This treatment group
also had a slightly higher level of blood BHB and a slightly lower
level of blood glucose on day 6 compared to day 13. While we
cannot rule out the possibility that the transient drop in weight and
slightly lower glucose on day 6 contributed to the survival benefit
seen when radiation and KC were combined, it is unlikely that this
played a major role since tumor shrinkage continued well after the
Figure 2. KetoCalH plus radiation treated animals experienced a loss of bioluminescence. (A) Radiation and KetoCalH plus radiation
animal imaged every three days. Color scheme represents signal intensity with red representing the highest intensity photon count. (B) (C)
Bioluminescent signal plotted as in vivo photon count versus days post-implantation.
doi:10.1371/journal.pone.0036197.g002
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remaining tumor cells did not begin to regrow after day 6 when
the animals began to rapidly regain their lost weight. Mukherjee et
al [14] described an increase in food consumption without a
concomitant increase in weight in their mouse model beginning
immediately following surgical implant of brain tumor cells.
Although we did not measure food intake in individual animals, we
did not see a noticeable change in food consumption in the KC-
fed animals that received radiation. The transient drop in weight
may be a result of the cumulative effects of therapy and dietary
change. One animal in the SD+radiation group survived longer
than the others in that cohort and had a persistent drop in weight.
Animal behavior serves as another way to assess the animal’s
health and well being. All animals were observed daily and we saw
no change in grooming and physical activity post treatment. This
animal remained active and apparently healthy until day 150 post-
implantation when its weight dropped, it showed tumor-related
symptoms and was euthanized.
Discussion
There has recently been renewed interest in the role of altered
cellular metabolism in cancer, and it has been suggested that
cellular metabolism may be an efficacious therapeutic target. To
this end we have examined the utility of increased blood ketones
on the efficacy of radiation for the treatment of glioma. KetoCalH
(KC) is a commercially available ketogenic diet used in the
treatment of pediatric epilepsy. Our results demonstrate that KC,
when administered ad libitum, enhances survival and slows tumor
growth in our mouse model of brain tumors. KC potentiates the
effect of radiation by extending survival beyond that seen with
radiation alone. Irradiated animals maintained on KC demon-
strated a complete loss of tumor-based bioluminescence, suggest-
ing tumor regression and the absence of viable tumor cells.
Tumors in this cohort of animals did not recur when animals were
put back on standard rodent chow.
The effectiveness of the ketogenic diet as an alternative
treatment for malignant glioma was first reported by Seyfried et
al [20,21] based on the idea that while normal brain can effectively
use ketones as an energy source, tumor cells cannot. Using the
syngeneic CT-2A and the xenograft U87 brain tumor models,
Zhou et al [19] showed that caloric restriction sufficient to cause a
drop in blood glucose also significantly increased survival.
Furthermore, when the ketogenic diet was given in restricted
amounts this effect was more pronounced. In contrast, when the
ketogenic diet or standard rodent chow was given ad libitum they
did not find a drop in blood glucose nor did they see a significant
change in survival. Recently, Maurer et al [22] used long-term
human glioma cell lines and rat hippocampal neurons to analyze
their utilization of ketone bodies in vitro. They showed that
although the enzymes required to metabolize ketones are present
in these glioma cells, the addition of 3-hydroxybutyrate to the
culture media did not protect the cells from glucose deprivation-
induced cell death, nor did it alter the cells’ proliferation,
migration or invasive properties. They also found that a ketogenic
diet did not alter tumor growth or extend the life of mice given an
orthotopic injection of LNT-229 glioma cells when compared to
mice maintained on standard diet. This is in contrast to our
previous work using a rodent ketogenic diet [13] and the work
described in this manuscript in which a human ketogenic
formulation was used (KetoCalH). The reason for this is unclear,
but may have to do with differences in the diet formulations.
Maurer et al [22] used a diet with a ratio of fats to carbohydrates
and protein of 2.7:1. The rodent diet we used [13] had a 6:1 ratio
and KC has a 4:1 ratio. Furthermore, there are a number of
papers in the literature demonstrating that ketones have
proapoptotic [23] and chemoattractant activity [24], in contrast
Figure 3. Blood ketone and glucose levels. Measurements of
animal ketone and glucose levels show higher bHB blood levels in
animals treated with KetoCalH. (A) bHB levels (B) Blood glucose
measurements. **=p,0.001; ***=p,0.0001.
doi:10.1371/journal.pone.0036197.g003
Figure 4. Animal weights. Weight measurements were taken every 3
days. Graph shows animals weights normalized to the average starting
weight of each group on day zero. (B) Arrow denotes a long-term
survivor 60 days following tumor implantation in the SD plus radiation
group.
doi:10.1371/journal.pone.0036197.g004
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ketones may be related, in part, to the cell line and/or model
system used.
Our investigation demonstrates a significant reduction of blood
glucose levels between SD and KC fed ad libitum. On day 6 and
day 13 blood glucose levels were lower in the KC group compared
to the SD group. Blood glucose levels were also lower between
Rad and KC+Rad on day 6 but not on day 13. Our results did not
demonstrate a correlation between circulating glucose levels and
survival, suggesting that the anti-tumor effects seen are likely to be
due to more than just reduced glucose levels. In addition, we did
not find a change in body weight between animals fed KC ad
libitum and animals fed SD ad libitum (Figure 3A). A drop in weight
was seen in animals treated with KC in combination with
radiation around day 6; however, animals regained this weight by
day 15 (Figure 3B). No direct relationship was seen between
weight loss and ketone or blood glucose levels or between blood
glucose levels and survival. The KC and KC plus radiation cohort
showed the longest survival without a statistical difference in either
blood glucose or weight loss. This agrees with the results of our
earlier work [13] and serves to further the notion that survival may
be independent of blood glucose levels.
In our previous work we used a syngeneic bioluminescent
intracranial tumor model to show that a ,6:1 (fat : protein+car-
bohydrate) rodent KD (Bioserv F3666 diet) caused a 6 day
increase in median survival of animals given unrestricted amounts
of the KD (p,0.0001) [13], despite the fact that there was no
measureable decrease in blood glucose. Furthermore, the dynam-
ics of tumor growth demonstrated by in vivo imaging of implanted
GL261-luc cells demonstrated a reduction in the rate of tumor
growth in animals fed KD [13], just as we now report using KC.
Molecular analyses of tumor and non-tumor tissue showed a
reduction in reactive oxygen species (ROS) in the tumor from
animals fed the KD. A reduction in ROS was also shown in
cultured GL261 cells when ketone bodies were added to complete
media in vitro, providing additional evidence for some efficacy even
in the absence of reduced glucose.
Seyfried et al [25] suggested that radiation and chemotherapy
may promote a more favorable metabolic environment (i.e.
increased glucose and glutamine) for glioma growth, thus reducing
long term survival. While there may be local increases in blood
glucose and/or glutamine in our model system, we did not see an
increase in blood glucose in the animals treated with radiation.
Furthermore, we did see a highly significant increase in long term
survival. The profound survival increase seen in animals treated
with KC and radiation may be due to the increased radiation
cytotoxicity of tumor cells as a result of sensitization by KC due to
the systemic effects of this diet. Similar results have been reported
in the literature. The regulation of glucose in cells treated with
cisplatin and carboplatin enhanced their sensitivity [26]. Cells
cultured with 2-deoxyglucose (2DG) had a 1.8 to 2.6 fold increase
in cellular sensitivity to cisplatin [26]. 2DG has been proposed as a
way to simulate the ketogenic diet and has been shown to enhance
radiation and chemotherapeutic response [27–30]. Preclinical
studies have served as the basis for the use of 2DG and other
dietary intervention in tandem with chemotherapy and radiation
[31]. Intravenous administration of 2DG 5–10 min prior to focal
irradiation caused 50–60% rates of tumor-free survival (‘‘cure’’) in
a number of tumor model systems [31]. Furthermore, a number of
studies using Akt inhibitors have demonstrated increased radio-
sensitivity in cells when activation of Akt is reduced [32,33,33],
thus providing another mechanism through which the KC may be
affecting radiosensitivity in these tumors.
There are a few case reports in the literature suggesting that a
ketogenic diet may be an effective therapy for the treatment of
human brain tumors [18,34,35]. These patients were not enrolled
in controlled trials and institutions have utilized varying formu-
lations of the KD; variations in adherence include restricted and
unrestricted approaches as well as differing durations of imple-
mentation. A medium chain triglyceride (MCT) formulation of the
ketogenic diet was implemented in 2 pediatric patients diagnosed
with advanced stage malignant astrocytomas [35]. The MCT-
based formulation of the ketogenic diet utilized by Nebeling et al is
composed of 60% MCT oil, 20% protein, 10% carbohydrates,
and 10% other dietary fats [34]. The patients tolerated the diet
well and experienced notable clinical improvements 4 to 5 years
after diagnosis [35]. Both patients underwent radiotherapy prior to
the administration of the ketogenic diet and one of the patients
also received chemotherapy. Both patients showed a decline in
tumor glucose metabolism which resulted in an improved
prognosis with greater median survival. More recently, Zuccoli
et al [18] reported on the use of a calorically restricted ketogenic
diet in a 65 year old woman diagnosed with a multifocal GBM.
Two weeks after the beginning of the KD the patient received
standard radiation and temozolomide treatment. Tumor regres-
sion was seen 2.5 months following diagnosis. Approximately 7
months after beginning the restricted ketogenic diet the patient
stopped following the calorically restricted diet and 3 months later
the tumor recurred and the patient succumbed approximately 20
months following initial diagnosis. This report demonstrated the
tolerability of a reduced calorie ketogenic diet in an adult
diagnosed with a GBM. In addition, the diet may have inhibited
tumor growth as it is unusual for a multifocal GBM to respond to
standard therapy alone in 2.5 months. Finally, it is likely that the
diet suppressed edema since the patient did not receive steroids
during the radiation and chemotherapy treatment and did not
appear to require them. Our previous work demonstrating a
reduction in the expression of the pro-inflammatory gene
cyclooxygenase 2 (COX-2) supports this as well [13].
In conclusion, we demonstrated that the effect of a ketogenic
diet was more than additive when used in combination with
radiation for the treatment of glioma in a mouse model system.
The ketogenic diet can be challenging to implement, we therefore
used the commercially available ketogenic diet KetoCalH (KC)
since this product is already in use for the clinical treatment of
refractory epilepsy. Mice fed KC alone had increased survival
compared to those fed SD. Furthermore, the combination of KC
and radiation led to the absence of detectable tumor in 9 of 11
mice. This response continued even after the mice were switched
back to SD 104 days following tumor implantation. With few
exceptions, when carried out appropriately the diet is well
tolerated in both mice and humans as demonstrated by a host of
animal studies as well as human case studies. The clinical
implementation of the ketogenic diet as a viable treatment
modality should be seriously considered in light of our new
insights into the cellular and molecular mechanisms of the diet as
well as the positive response seen in the available clinical
implementations.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of St. Joseph’s Hospital and Medical Center (protocol
Ketogenic Diet as an Adjuvant to Radiation Therapy
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ketamine/xylazine anesthesia, and every effort was made to
minimize suffering.
GL261 mouse model of glioma
GL261 cells were obtained from DCTD Tumor Repository
(NCI, Frederick, MD) and grown in DMEM supplemented with
10% fetal calf serum (FCS) at 37uC with 5% CO2. To facilitate a
quantitative measurement of tumor growth rate GL261 cells were
stably transfected with the gene encoding luc2 using the
pGL4.51[luc2/CMV/Neo] vector (Promega Corp, Madison, WI)
and FuGENEH 6 Transfection Reagent (Roche Applied Science,
Indianapolis, IN) following conditions specified by the manufac-
turer. Stable transfectants were selected and maintained in
Dulbecco’s modified eagles medium (DMEM) containing 10%
FCS and 100 mg/ml GeneticinH (G418, Invitrogen Corp,
Carlsbad, CA). These cells were designated GL261-luc2 and their
growth rate is equivalent to the parental GL261 cell line. Cells
were harvested by trypsinization, washed and resuspended at a
concentration of 1–2610
7 cells/ml in DMEM without FCS and
implanted into ten week old C57BL/6-cBrd/cBrd/Cr (albino
C57BL/6) mice (National Cancer Institute at Frederick Animal
Production Program, Frederick, MD) at an average weight of 20
grams as described [13]. The implantation method has been
described elsewhere [36]. Briefly, animals were anesthetized by an
intraperitoneal injection of ketamine (10 mg/kg) and xylazine
(80 mg/kg), placed in a stereotactic apparatus and an incision was
made over the cranial midline. A burrhole was made 0.1 mm
posterior to the bregma and 2.3 mm to the right of the midline. A
needle was inserted to a depth of 3 mm and withdrawn 0.4 mm to
a depth of 2.6 mm. Two ml of GL261-luc2 cells (10
7 cells/ml) were
infused over the course of 3 minutes. The burrhole was closed with
bonewax and the incision was sutured. Mice were housed in
groups of 5 in the animal care facility of St. Joseph’s Hospital and
Medical Center in rooms with controlled temperature and
humidity under a 12-hour light-dark cycle according to the
guidelines outlined in the NIH Guide for Care and Use of
Laboratory Animals.
Treatment and animal monitoring
Following surgery, animals were fed standard rodent chow for 3
days. Animals were then randomized to remain on standard
rodent chow (SD) ad libitum or changed to KetoCalH (KC) ad
libitum. KetoCalH was obtained directly from the manufacturer
and is a nutritionally complete diet providing a 4:1 ratio of fats to
carbohydrates plus protein (72% fat, 15% protein, and 3%
carbohydrate; for complete nutritional information see http://
www.shsna.com/pages/ketocal41.htm). A paste was prepared by
mixing KetoCalH powder with water (2:1). Animals in each cage
received a cubic inch of the paste each day which was sufficient to
provide ad libitum feeding.
On days 3 and 5 post-implantation animals receiving radiation
were given an intraperitoneal injection of xylazine (10 mg/kg) and
ketamine (80 mg/kg), shielded and positioned in the RS 2000 X-
Ray Biological Irradiator (Rad Source Technologies, Suwanee,
GA) such that only their head received 4 Gy of radiation at 2 Gy
per minute. Animals received two fractions of radiation (4 Gy
each) to more closely approximate the fractionated course of
treatment that patients would undergo [37].
Bioluminescence was analyzed every third day to quantify
tumor burden [13]. Animals received a subcutaneous (s.c.)
injection of 150 mg luciferin/kg body weight 15 min prior to in
vivo imaging using an IVISH Spectrum in vivo imaging system
(Caliper Life Sciences, Hopkinton, MA). Tumor cells were
detectable 3 days post implantation (the first day they were
imaged) and quantitation was done using the system’s Living
ImageH 3.1 software.
Serum b-hydroxybutyrate levels were measured using a Keto-
Site reflectance meter (GDS Diagnostics, Elkhart, IN) and blood
glucose levels were tested using a HemoCue Glucose 201 System
(HemoCue USA, Lake Forest, CA) on blood obtained from tail
clips as described [13]. Animals were weighed every 3 days to
ensure that all the animals were gaining weight in an equivalent
manner. Animals were euthanized upon occurrence of visible
symptoms of impending death such as hunched posture, reduced
mobility and weight loss [13,38].
Statistical Analysis
Survival data was analyzed using Kaplan-Meier plots and log-
rank statistics (GraphPad PrismH v 5.04, GraphPad Software, San
Diego, CA). Survival data from SD alone, KC alone, SD+radia-
tion, and KC+radiation were examined for interaction effects
using Cox Proportional Hazards. The model examined SD and
KC in the context of radiation and radiation+KC. The method
used right censoring, robust variance estimates, and Breslow’s
method for ties with a convergence tolerance of 0.0001, allowing
colinearity.
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